Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · regulatory

Psychedelics get a hearing at FDA

15 September 2026 · By · Wire by Fusion42

Published

15 September 2026

Topic

regulatory

◆ Sectors

Health

◆ Geography

United States

◆ Source

Read at capradio.org →

◆ Verified

Fusion42 · 15 September 2026 · Fusion42 review

The FDA held a hearing on the potential use of psychedelics in mental healthcare, focusing on administration and safety as research progresses and the Trump administration signals support for psychedelic drug approvals.

This Wire brief sits within Fusion42's coverage of Health, and 3 sources have reported it between 14 Sep 2026 and 15 Sep 2026.

◆ ◆ The Wire takeaway

You need to prepare for psychedelics to become tightly regulated therapies requiring specialised administration and training. This shifts mental health opportunities toward providers who can meet strict safety standards.

◆ Coverage

3 sources · first reported 14 Sep 2026 · latest 15 Sep 2026

◆ Related on Wire

◆ Topics

HealthpsychedelicsFDAdrug-approvalmental-healthregulation